Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

about

EEG Microstates Change in Response to Increase in Dopaminergic Stimulation in Typical Parkinson's Disease Patients

P2860

Q58122162-CE490363-B63B-4112-A567-4D941439F213

P2860

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Item

http://www.wikidata.org/entity/Q49949879

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

@en

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

@nl

type

Item

label

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

@en

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

@nl

prefLabel

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

@en

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

@nl

P1476

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

@en

P275

Creative Commons Attribution 4.0 International

P2860

Thinking outside a less intact box: thalamic dopamine D2 receptor densities are negatively related to psychometric creativity in healthy individuals

The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders

The immunoregulatory role of dopamine: an update

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia

Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes

Striatal cholinergic interneuron regulation and circuit effects

A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo.

Role of endogenous cannabinoids in synaptic signaling

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11095-017-2333-X

http://www.w3.org/2001/XMLSchema#string

P4011

ea6c582667d191ff5d058e37ad2e50e6d8580dee

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth C de Lange

Willem Johan van den Brink

Semra Palic

Isabelle Köhler

P577

2018-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29450650

http://www.w3.org/2001/XMLSchema#string

P921

endocrine system

dopamine

cell surface receptor

mechanism of action

membrane proteins

biomedical investigative technique

Anagraw anesur

P932

5814527

http://www.w3.org/2001/XMLSchema#string

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

about

P2860

P2860

Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

description

name

type

label

prefLabel

P1433

P1476

P275

P2860

P304

P31

P356

P4011

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P275

P2860

P304

P31

P356

P4011

P433

P478

P50

P577

P698

P921

P932